A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Shanghai Chest Hospital
Pfizer
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
Ohio State University Comprehensive Cancer Center
Blueprint Medicines Corporation
Cantargia AB
Blueprint Medicines Corporation
Swiss Cancer Institute
BioNTech SE
Novartis
Masonic Cancer Center, University of Minnesota
Sanofi
University of Arizona
Cancer Research and Biostatistics Clinical Trials Consortium
Barbara Ann Karmanos Cancer Institute
SCRI Development Innovations, LLC